TABRECTA FDA approval date

The FDA approved TABRECTA on 6 May 2020.

FDA approval date
6 May 2020

Drug identity has not yet been verified against registry records

Also recorded as CAPMATINIB HYDROCHLORIDE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2020-05-06DayTABRECTAFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA213591", "applicant_as_listed_by_fda": "NOVARTIS PHARM", "brand_names": ["TABRECTA"], "active_ingredients": ["CAPMATINIB HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20200506", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026